Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis
An immune checkpoint blockade with mAbs to PD-1 and PD-L1 is an expanding therapeutic option for mNSCLC patients. This treatment strategy is based on the use of mAbs able to restore the anti-tumor activity of intratumoral T cells inhibited by PD-1 binding to PD-L1/2 on tumor and inflammatory cells....
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
MDPI AG
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/62314baa55cc425bb501c2b7b1efcaef |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:62314baa55cc425bb501c2b7b1efcaef |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:62314baa55cc425bb501c2b7b1efcaef2021-11-25T18:11:25ZDistinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis10.3390/life111112352075-1729https://doaj.org/article/62314baa55cc425bb501c2b7b1efcaef2021-11-01T00:00:00Zhttps://www.mdpi.com/2075-1729/11/11/1235https://doaj.org/toc/2075-1729An immune checkpoint blockade with mAbs to PD-1 and PD-L1 is an expanding therapeutic option for mNSCLC patients. This treatment strategy is based on the use of mAbs able to restore the anti-tumor activity of intratumoral T cells inhibited by PD-1 binding to PD-L1/2 on tumor and inflammatory cells. It has been speculated that a chronic status of systemic inflammation as well as the immunosenescence physiologically occurring in elderly patients may affect the efficacy of the treatment and the occurrence of irAEs. We performed a multi-institutional retrospective study aimed at evaluating the effects of these mAbs (nivolumab or atezolizumab) in 117 mNSCLC patients younger (90 cases) and older (27 cases) than 75 years in correlation with multiple inflammatory parameters (NLR, CRP, ESR, LDH and PCT). No differences were observed when the cohorts were compared in terms of the frequency of PFS, OS, inflammatory markers and immune-related adverse events (irAEs). Similarly, the occurrence of irAEs was strictly correlated with a prolonged OS survival in both groups. On the contrary, a negative correlation between the high baseline levels of inflammatory markers and OS could be demonstrated in the younger cohort only. Overall, PD-1/PD-L1-blocking mAbs were equally effective in young and elderly mNSCLC patients; however, the detrimental influence of a systemic inflammation at the baseline was only observed in young patients, suggesting different aging-related inflammation immunoregulative effects.Valerio NardoneRocco GiannicolaDiana GiannarelliRita Emilena SaladinoDomenico AzzarelloCaterina RomeoGiovanna BiancoMaria Rosaria RizzoIrene Di MeoAntonio NesciPierpaolo PastinaAntonia Consuelo FalzeaDaniele CaraccioloAlfonso ReginelliMichele CaragliaAmalia LuceLuciano MuttiAntonio GiordanoSalvatore CappabiancaLuigi PirtoliVito BarbieriPierfrancesco TassonePierosandro TagliaferriPierpaolo CorrealeMDPI AGarticleimmune checkpoint blockademetastatic non-small-cell lung cancerreal-world evidence studyageinflammatory markersimmunotherapyScienceQENLife, Vol 11, Iss 1235, p 1235 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
immune checkpoint blockade metastatic non-small-cell lung cancer real-world evidence study age inflammatory markers immunotherapy Science Q |
| spellingShingle |
immune checkpoint blockade metastatic non-small-cell lung cancer real-world evidence study age inflammatory markers immunotherapy Science Q Valerio Nardone Rocco Giannicola Diana Giannarelli Rita Emilena Saladino Domenico Azzarello Caterina Romeo Giovanna Bianco Maria Rosaria Rizzo Irene Di Meo Antonio Nesci Pierpaolo Pastina Antonia Consuelo Falzea Daniele Caracciolo Alfonso Reginelli Michele Caraglia Amalia Luce Luciano Mutti Antonio Giordano Salvatore Cappabianca Luigi Pirtoli Vito Barbieri Pierfrancesco Tassone Pierosandro Tagliaferri Pierpaolo Correale Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis |
| description |
An immune checkpoint blockade with mAbs to PD-1 and PD-L1 is an expanding therapeutic option for mNSCLC patients. This treatment strategy is based on the use of mAbs able to restore the anti-tumor activity of intratumoral T cells inhibited by PD-1 binding to PD-L1/2 on tumor and inflammatory cells. It has been speculated that a chronic status of systemic inflammation as well as the immunosenescence physiologically occurring in elderly patients may affect the efficacy of the treatment and the occurrence of irAEs. We performed a multi-institutional retrospective study aimed at evaluating the effects of these mAbs (nivolumab or atezolizumab) in 117 mNSCLC patients younger (90 cases) and older (27 cases) than 75 years in correlation with multiple inflammatory parameters (NLR, CRP, ESR, LDH and PCT). No differences were observed when the cohorts were compared in terms of the frequency of PFS, OS, inflammatory markers and immune-related adverse events (irAEs). Similarly, the occurrence of irAEs was strictly correlated with a prolonged OS survival in both groups. On the contrary, a negative correlation between the high baseline levels of inflammatory markers and OS could be demonstrated in the younger cohort only. Overall, PD-1/PD-L1-blocking mAbs were equally effective in young and elderly mNSCLC patients; however, the detrimental influence of a systemic inflammation at the baseline was only observed in young patients, suggesting different aging-related inflammation immunoregulative effects. |
| format |
article |
| author |
Valerio Nardone Rocco Giannicola Diana Giannarelli Rita Emilena Saladino Domenico Azzarello Caterina Romeo Giovanna Bianco Maria Rosaria Rizzo Irene Di Meo Antonio Nesci Pierpaolo Pastina Antonia Consuelo Falzea Daniele Caracciolo Alfonso Reginelli Michele Caraglia Amalia Luce Luciano Mutti Antonio Giordano Salvatore Cappabianca Luigi Pirtoli Vito Barbieri Pierfrancesco Tassone Pierosandro Tagliaferri Pierpaolo Correale |
| author_facet |
Valerio Nardone Rocco Giannicola Diana Giannarelli Rita Emilena Saladino Domenico Azzarello Caterina Romeo Giovanna Bianco Maria Rosaria Rizzo Irene Di Meo Antonio Nesci Pierpaolo Pastina Antonia Consuelo Falzea Daniele Caracciolo Alfonso Reginelli Michele Caraglia Amalia Luce Luciano Mutti Antonio Giordano Salvatore Cappabianca Luigi Pirtoli Vito Barbieri Pierfrancesco Tassone Pierosandro Tagliaferri Pierpaolo Correale |
| author_sort |
Valerio Nardone |
| title |
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis |
| title_short |
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis |
| title_full |
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis |
| title_fullStr |
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis |
| title_full_unstemmed |
Distinctive Role of the Systemic Inflammatory Profile in Non-Small-Cell Lung Cancer Younger and Elderly Patients Treated with a PD-1 Immune Checkpoint Blockade: A Real-World Retrospective Multi-Institutional Analysis |
| title_sort |
distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: a real-world retrospective multi-institutional analysis |
| publisher |
MDPI AG |
| publishDate |
2021 |
| url |
https://doaj.org/article/62314baa55cc425bb501c2b7b1efcaef |
| work_keys_str_mv |
AT valerionardone distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT roccogiannicola distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT dianagiannarelli distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT ritaemilenasaladino distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT domenicoazzarello distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT caterinaromeo distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT giovannabianco distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT mariarosariarizzo distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT irenedimeo distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT antonionesci distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT pierpaolopastina distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT antoniaconsuelofalzea distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT danielecaracciolo distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT alfonsoreginelli distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT michelecaraglia distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT amalialuce distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT lucianomutti distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT antoniogiordano distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT salvatorecappabianca distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT luigipirtoli distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT vitobarbieri distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT pierfrancescotassone distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT pierosandrotagliaferri distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis AT pierpaolocorreale distinctiveroleofthesystemicinflammatoryprofileinnonsmallcelllungcanceryoungerandelderlypatientstreatedwithapd1immunecheckpointblockadearealworldretrospectivemultiinstitutionalanalysis |
| _version_ |
1718411500270387200 |